Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. The company's world-renowned medical and scientific advisory board is progressing a robust research and development (R&D) pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems.